Amplification Defines a Genetically Distinct Subset of Angiosarcomas.

Biomolecules

Division of Pediatric Oncology, Department of Pediatrics, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, 3501 Civic Center Boulevard, CTRB 3064, Philadelphia, PA 19104, USA.

Published: August 2022

Angiosarcoma is a rare, devastating malignancy with few curative options for disseminated disease. We analyzed a recently published genomic data set of 48 angiosarcomas and noticed recurrent amplifications of -cluster genes in 33% of patients. genes are master regulators of embryonic vascular development and adult neovascularization, which provides a molecular rationale to suspect that amplified genes act as oncogenes in angiosarcoma. amplifications typically affected multiple pro-angiogenic genes and co-occurred with amplifications of and whereas the overall mutation rate in these tumors was relatively low. amplifications were found most commonly in angiosarcomas located in the breast and were rare in angiosarcomas arising in sun-exposed areas on the head, neck, face and scalp. Our data suggest that -amplified angiosarcoma is a distinct molecular subgroup. Efforts to develop therapies targeting oncogenic gene expression in AML and other sarcomas may have relevance for -amplified angiosarcoma.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406048PMC
http://dx.doi.org/10.3390/biom12081124DOI Listing

Publication Analysis

Top Keywords

-amplified angiosarcoma
8
amplification defines
4
defines genetically
4
genetically distinct
4
distinct subset
4
angiosarcomas
4
subset angiosarcomas
4
angiosarcoma
4
angiosarcomas angiosarcoma
4
angiosarcoma rare
4

Similar Publications

Angiosarcoma (AS) is a malignant vascular neoplasm comprising neoplastic endothelial cells accounting for 1%-4% of soft tissue sarcomas. While lymphedema-associated and post-irradiation ASs are almost always driven by a high-level amplification of MYC (8q24), sporadic ASs, including those of breast parenchymal origin, typically lack MYC amplification. Here, we report a case of sporadic breast MYC-amplified AS in a 19-year-old female with no history of lymphedema or irradiation, who was referred to our hospital for an enlarging right breast mass.

View Article and Find Full Text PDF

Both primary and secondary breast angiosarcoma (AS) are characterized by multifocal presentation and aggressive behavior. Despite multimodality therapy, local and distant relapse rates remain high. Therefore, neoadjuvant chemotherapy (NACT) is employed to improve the R0 resection rates and survival, but its benefits remain controversial.

View Article and Find Full Text PDF

Amplification Defines a Genetically Distinct Subset of Angiosarcomas.

Biomolecules

August 2022

Division of Pediatric Oncology, Department of Pediatrics, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, 3501 Civic Center Boulevard, CTRB 3064, Philadelphia, PA 19104, USA.

Angiosarcoma is a rare, devastating malignancy with few curative options for disseminated disease. We analyzed a recently published genomic data set of 48 angiosarcomas and noticed recurrent amplifications of -cluster genes in 33% of patients. genes are master regulators of embryonic vascular development and adult neovascularization, which provides a molecular rationale to suspect that amplified genes act as oncogenes in angiosarcoma.

View Article and Find Full Text PDF

Overall and net survival of patients with sarcoma between 2005 and 2010: Results from the French Network of Cancer Registries (FRANCIM).

Cancer

July 2022

Epicene Team, Bordeaux Population Health Research Center, French National Institute of Health and Medical Research (INSERM) UMR 1219, University of Bordeaux, Bordeaux, France.

Background: Sarcomas are rare, heterogeneous, ubiquitously localized malignancies with many histologic subtypes and genomic patterns. The survival of patients with sarcoma has rarely been described based on this heterogeneity; therefore, the authors' objective was to estimate survival outcomes in patients who had sarcomas using the 2020 version of the World Health Organization classification of soft tissue and bone tumors.

Methods: Patients older than 15 years who had incident sarcoma diagnosed between 2005 and 2010 were extracted from 14 French population-based cancer registries covering 18% of the French metropolitan population.

View Article and Find Full Text PDF

Comparison of Serological and Molecular Assays for Species in Dogs with Hemangiosarcoma.

Pathogens

June 2021

Intracellular Pathogens Research Laboratory, Comparative Medicine Institute, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, USA.

Currently, a gold standard diagnostic test for infection in dogs is lacking. This represents a critical limitation for the development and evaluation of new diagnostic tests, as well as for the diagnosis of, and research on, bartonellosis in dogs. This retrospective observational study aims to compare the results of commonly performed and newly-reported spp.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!